Recruiting

Aspirin Doses

Sponsor:

Ohio State University

Code:

NCT06468202

Conditions

Hypertensive Disorders of Pregnancy

Preeclampsia

Gestational Hypertension

Eligibility Criteria

Sex: Female

Age: 14 - 35

Healthy Volunteers: Not accepted

Interventions

Aspirin 81 mg

Aspirin 162 mg

Study Details

Brief summary:

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.

Conditions

Hypertensive Disorders of Pregnancy

Preeclampsia

Gestational Hypertension

Study ID

NCT06468202

Start date

Oct 18, 2024

Status verified date

Apr, 2026

Completion date

Feb 1, 2030

Anticipated

Primary completion date

Jan 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 14 - 35

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. live intrauterine gestation ≤16 6/7 weeks gestational age based on best clinical obstetric estimate,
2. age 14 years or older and able to provide informed consent,
3. at least one of the following high-risk criteria: i) any prior pregnancy complicated by preeclampsia ii) current pregnancy complicated by chronic hypertension diagnosed before randomization (ACOG) iii) pre-gestational diabetes (on medication for diabetes prior to pregnancy, or diabetes is diagnosed prior to randomization with hemoglobin A1C of 6.5% or greater or abnormal 3-hour glucose tolerance test) iv) twin gestation (including higher order pregnancy reduced to twins prior to 14 weeks) v) chronic kidney disease vi) autoimmune disease (e.g., antiphospholipid syndrome, systemic lupus erythematous)
4. or two or more moderate-risk criteria for HDP (per USPSTF), i) nulliparity (no prior delivery at or after 20 weeks 0 days of gestation) ii) obesity (body mass index ≥30 kg/m2 at time of randomization) iii) age ≥35 years (at time of expected estimated due date) iv) Black race v) low income vi) personal risk factors (previous pregnancy with low birth weight or SGA infant, previous adverse pregnancy outcome \[unexplained stillbirth\], placental abruption, interval >10 years between pregnancies) vii) Family history of preeclampsia (i.e., mother or sister) viii) In vitro fertilization
5. patient not currently on aspirin OR patient on aspirin for obstetrical indications (e.g., related to IVF, or HDP) and: i- randomized before 130/7 weeks gestation, or ii- randomized on or after 13 0/7 weeks gestation and started aspirin within 2 weeks prior to randomization (e.g., aspirin started for HDP prevention at 12 0/7 weeks and patient randomized at 13 2/7 weeks).

Exclusion Criteria:

1. known allergy or hypersensitivity to aspirin or any medical condition where aspirin is contraindicated (e.g., active peptic ulcer disease, nasal polyps, NSAID-induced asthma, active gastrointestinal bleeding, known G6PD deficiency, severe hepatic dysfunction, bleeding disorders, history of bariatric surgery),
2. current or planned aspirin use in pregnancy for non-obstetrical indication (e.g., prior stroke/prior myocardial infraction),
3. age < 14 years,
4. involuntarily confined or detained,
5. considered as having a diminished decision-making capacity,
6. obstetrical ultrasound suspicious for major congenital abnormality, known or suspected fetal aneuploidy, fetal demise, or planned pregnancy termination,
7. participation in another trial that affects the primary outcome, without prior approval of the PI,
8. plan to deliver at an outside participating site with inability to obtain medical records,
9. monoamniotic twin gestation because of the risk of fetal demise and preterm delivery,
10. participation in this trial in prior pregnancy,
11. triplet or higher order pregnancy.

Study Design

Enrollment

10742 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: 81 mg Aspirin

Treatment A consisting of 81mg of aspirin (1 pill of 81mg \& 1 matching placebo) daily

experimental: 162 mg Aspirin

Treatment B consisting of 162mg of aspirin (2 pills, each of 81mg) daily

Interventions

Aspirin 81 mg

Participants will be assigned to 81mg Aspirin

Aspirin 162 mg

Participants will be assigned to 162mg Aspirin

Primary outcome measure

  • Hypertensive Disorder of Pregnancy (HDP) [ Time Frame: From >20 weeks gestation until hospital discharge following delivery, up to 22 weeks ]

Central Contacts and Locations

Central contacts

Locations

University of Alabama at Birmingham

Recruiting

Birmingham, Alabama, United States, 35233

Contacts

Akila Subramaniam, MD, MPH

asubramaniam@uabmc.edu

Cedars Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Principal Investigator:

Kimberly Gregory, MD, MPH

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94158

Contacts

Principal Investigator:

Mary Norton, MD

Northwestern University

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Michelle Kominiarek, MD

Michelle.Kominiarek@nm.org

Catherine Arguelles

catherine.marek@nm.org

Principal Investigator:

Michelle Kominiarek, MD

University of Mississippi

Recruiting

Jackson, Mississippi, United States, 39216

Contacts

Rachel Morris, MD

morris@umc.edu

Laura Coats

Lcoats@umc.edu

Principal Investigator:

Rachel Morris, MD

University of New Mexico

Recruiting

Albuquerque, New Mexico, United States, 27710

Contacts

Christina Yarrington, MD

CYarrington@salud.unm.edu

Principal Investigator:

Christina Yarrington, MD

Columbia University

Recruiting

New York, New York, United States, 10032

Contacts

Principal Investigator:

Matthew Hoffman, MD

University of North Carolina, Chapel Hill

Recruiting

Chapel Hill, North Carolina, United States, 27514

Contacts

Principal Investigator:

Kim Boggess, MD

The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine

Recruiting

Columbus, Ohio, United States, 43210

Contacts

University of Pittsburg Magee

Recruiting

Pittsburgh, Pennsylvania, United States, 15213

Contacts

Hyagriv Simhan, MD

simhhn@upmc.edu

Jeanette Boyce

tessje@upmc.edu

Principal Investigator:

Hyagriv Simhan, MD

Brown University

Recruiting

Providence, Rhode Island, United States, 02905

Contacts

William Grobman, MD, MBA

WGrobman@KentRI.org

University of Texas, Houston

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Baha Sibai, MD

University of Utah

Recruiting

Salt Lake City, Utah, United States, 84132

Contacts

Inova HealthSystem

Recruiting

Falls Church, Virginia, United States, 22042

Contacts

Antonio Saad, MD

Antonio.Saad@inova.org

Eastern Virginia Medical School - Old Dominion University

Recruiting

Norfolk, Virginia, United States, 23501

Contacts

George Saade, MD

SaadeGR@EVMS.edu

Kristin Ayers

ayerskl@evms.edu

Principal Investigator:

George Saade, MD

Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Anna Palatnik, MD

apalatnik@mcw.edu

More Information

Sponsor

Ohio State University

Last update posted

May 4, 2026

Last verified

Apr, 2026

Keywords

  • Hypertensive disorders of pregnancy
  • Aspirin treatment
  • Pregnancy
  • Preeclampsia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Ohio State University on 2026-05-04.